Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Hum Mol Genet ; 30(13): 1247-1258, 2021 06 17.
Article in English | MEDLINE | ID: covidwho-1216653

ABSTRACT

The systematic identification of host genetic risk factors is essential for the understanding and treatment of coronavirus disease 2019 (COVID-19). By performing a meta-analysis of two independent genome-wide association summary datasets (N = 680 128), a novel locus at 21q22.11 was identified to be associated with COVID-19 infection (rs9976829 in IFNAR2-IL10RB, odds ratio = 1.16, 95% confidence interval = 1.09-1.23, P = 2.57 × 10-6). The rs9976829 represents a strong splicing quantitative trait locus for both IFNAR2 and IL10RB genes, especially in lung tissue (P = 1.8 × 10-24). Integrative genomics analysis of combining genome-wide association study with expression quantitative trait locus data showed the expression variations of IFNAR2 and IL10RB have prominent effects on COVID-19 in various types of tissues, especially in lung tissue. The majority of IFNAR2-expressing cells were dendritic cells (40%) and plasmacytoid dendritic cells (38.5%), and IL10RB-expressing cells were mainly nonclassical monocytes (29.6%). IFNAR2 and IL10RB are targeted by several interferons-related drugs. Together, our results uncover 21q22.11 as a novel susceptibility locus for COVID-19, in which individuals with G alleles of rs9976829 have a higher probability of COVID-19 susceptibility than those with non-G alleles.


Subject(s)
COVID-19/genetics , Chromosomes, Human, Pair 21 , Interleukin-10 Receptor beta Subunit/genetics , Receptor, Interferon alpha-beta/genetics , Alleles , Antiviral Agents/pharmacology , COVID-19/immunology , Cytokines/genetics , Genetic Predisposition to Disease , Genome-Wide Association Study , Genomics/methods , Humans , Molecular Targeted Therapy , Polymorphism, Single Nucleotide , Quantitative Trait Loci , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL